Objective To explore the rules and characteristics of the adverse drug reactions(ADRs)of three Chinese patent medicines and three herbal formulas for the treatment of COVID-19,and to provide a reference for clinical s...Objective To explore the rules and characteristics of the adverse drug reactions(ADRs)of three Chinese patent medicines and three herbal formulas for the treatment of COVID-19,and to provide a reference for clinical safe medication.Methods The cases and ADR reports of the three Chinese patent medicines and three herbal formulas in PubMed,Web of Science,Springer Link,CNKI,Wanfang and VIP database were retrieved from December 2019 to May 2021.Then we extracted and analyzed the effective information included in the literature.Results and Conclusion According to the pre-developed retrieval plan,a total of 136 documents were obtained,and a total of 6 documents met the inclusion criteria finally.553 patients used three Chinese patent medicines and three herbal formulas,and there were 133 cases of adverse reactions.The adverse reactions of patients taking the three Chinese patent medicines and three herbal formulas can all be explained under the theory of traditional Chinese medicine,and the adverse reactions can be eliminated by adding or subtracting the flavor of the medicine or stopping the medicine.展开更多
Objective:To systematically review the efficacy and clinical safety of Qizhi Weitong Granules(气滞胃痛颗粒)(QZWT)in the treatment of irritable bowel syndrome with predominant constipation(IBS-C).Methods:Randomized con...Objective:To systematically review the efficacy and clinical safety of Qizhi Weitong Granules(气滞胃痛颗粒)(QZWT)in the treatment of irritable bowel syndrome with predominant constipation(IBS-C).Methods:Randomized controlled trials(RCTs)of QZWT in patients with IBS-C were retrieved from Pub Med,EMBASE,Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang,Chinese Scientific Journals Database(VIP),and Chinese Biological Medical Database(CBM)from inception to December 3,2022.Conventional meta-analysis with random-effects model or fixed-effects model and trial sequential analysis(TSA)were performed by Review Manager 5.4,Stata and TSA software.Results:A total of 4 RCTs and 368 patients with IBS-C were included in this study.The findings of the meta-analysis indicated that the cure and efficacy rate of the experimental group was significantly higher than that of the control group[RR=2.19;(95%CI,1.35–3.55),P<0.01;RR=1.14;(95%CI,1.03–1.27),P<0.05],while the result of Bristol Score was negative.The funnel plot was probably symmetry,and the P value was>0.05 in the Egger test,which confirmed the nonexistence of significant publication bias in this outcome.TSA showed the cumulative z-value crossed the traditional threshold and TSA threshold,while it didn't get to the required information size.Finally,2 studies reported adverse events after QZWT treatment,including 3 cases of diarrhea.No serious adverse events were reported.Conclusion:QZWT was an effective and safe complementary therapy in the treatment of IBS-C with no obvious adverse reactions.TSA analysis confirmed our meta-analysis results.Therefore,QZWT may be a potential candidate for the treatment of IBS-C.However,due to the limited quality of current studies,more long-term,randomized,double-blinded clinical trials are needed in future studies.展开更多
Objective:To evaluate the efficacy and safety of Yiqi Huoxue oral Chinese patent medicine in the treatment of angina pectoris.Methods:the databases of EMBASE,PubMed,CNKI,Wanfang and VIP were searched by computer,and t...Objective:To evaluate the efficacy and safety of Yiqi Huoxue oral Chinese patent medicine in the treatment of angina pectoris.Methods:the databases of EMBASE,PubMed,CNKI,Wanfang and VIP were searched by computer,and the randomized controlled trial(RCT)of Yiqi Huoxue Chinese patent medicine in the treatment of angina pectoris of coronary heart disease(CHD)was searched until December 2019.By using stata15.1 software,the total clinical effective rate,the improvement rate of ECG,the improvement rate of angina pectoris,the attack frequency and duration of angina pectoris were taken as the outcome indicators for network meta analysis and mapping.Results:51 RCTs were included,including 9 kinds of traditional Chinese medicine.The results of network meta analysis showed that:in terms of clinical total effective rate,the order was Shexiang Baoxin Pill(78.2%)>xueshuanxinming tablet>Dengzhan Shengmai capsule>Shengui Capsule>Tongxinluo capsule>Tongmai Yangxin pill>Yangxin tablet>Shexiang Tongxin drop pill>Naoxintong capsule;the improvement of ECG was Tongmai Yangxin pill(85.2%)>Yangxin tablet>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Shexiang Baoxin Pill>Tongxinluo gum Capsule>Shengui Capsule>Naoxintong capsule;in order to reduce the frequency and duration of angina pectoris,they are conventional Naoxintong capsule(88.6%)>Shengui Capsule>Tongmai Yangxin pill>Shexiang Baoxin Pill>xueshuanxinmingpian>Tongxinluo capsule>Shexiang Tongxin drop pill>Dengzhan Shengmai capsule;Shexiang Baoxin Pill(66.9%)>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Tongxinluo capsule>xueshuanxinmingning capsule Tablet>Tongmai Yangxin pill.Conclusion:Traditional Chinese medicine combined with western medicine has obvious advantages in the treatment of angina pectoris.Shexiang Baoxin Pill,Dengzhan Shengmai capsule and Tongmai Yangxin pill can be given priority.展开更多
A capillary electrophoresis with electrochemical detection(CE-ED) method was developed for the quality analysis of herbal medicine products prepared from the same herb of Herba Sarcandrae: Fufang Caoshanhu tablets,...A capillary electrophoresis with electrochemical detection(CE-ED) method was developed for the quality analysis of herbal medicine products prepared from the same herb of Herba Sarcandrae: Fufang Caoshanhu tablets, Qingrexiaoyanning capsules, and Xuekang oral liquids. Under the optimal analysis conditions, the low detection limit[l.0×10^-7 mol/L(S/N=3)] and the wide linear range(1.0×10^-7-1.0×10^-4 mol/L) were obtained for quality standard compound of isofraxidin. The precisions of the peak current and the migration time(as RSDs) for the real sample analysis were 2.0%-2.6%, and 1.2%-1.8% for isofraxidin, respectively. The contents of isofraxidin detected were 15.77 μg/tablet, 0.48 mg/capsule, 1.2 mg/ampoule(Jiangxi), and 0.44 mg/ampoule(Dalian) for Fufang Caoshanhu tablets, Qingrexiaoyanning capsules, and Xuekang oral liquids from different manufacturers, respectively. Quality estimate was conducted by comparing the contents of isofraxidin in the herbal medicine products with the demanded values of Chinese pharmacopeia. In addition, based on their own unique CE-ED profiles(namely, CE-ED electropherograms) the Xuekang oral liquids from the different manufacturers could be easily identified.展开更多
目的:运用网状Meta分析方法系统评价中成药联合常规西药治疗稳定型心绞痛的有效性及安全性。方法:计算机检索PubMed、The Cochrane Library、Embase、Web of Science、万方、维普、知网和中国生物医学文献数据库,搜集中成药联合常规西...目的:运用网状Meta分析方法系统评价中成药联合常规西药治疗稳定型心绞痛的有效性及安全性。方法:计算机检索PubMed、The Cochrane Library、Embase、Web of Science、万方、维普、知网和中国生物医学文献数据库,搜集中成药联合常规西药治疗稳定型心绞痛的随机对照试验,检索时限均为建库至2022年2月10日。采用RevMan5.3、STATA15.1软件进行数据统计分析。结果:共纳入70项随机对照试验,包括6 973例患者,涉及7种中成药。网状Meta分析结果显示:(1)在提高心绞痛疗效方面,排序依次为养心氏片+常规西药>麝香保心丸+常规西药>冠心舒通胶囊+常规西药>芪参益气滴丸+常规西药>丹蒌片+常规西药>心可舒片+常规西药>益心舒胶囊+常规西药>常规西药;(2)在提高心电图疗效方面,排序依次为芪参益气滴丸+常规西药>养心氏片+常规西药>麝香保心丸+常规西药>冠心舒通胶囊+常规西药>心可舒片+常规西药>益心舒胶囊+常规西药>丹蒌片+常规西药>常规西药;(3)在升高高密度脂蛋白胆固醇方面,排序依次为冠心舒通胶囊+常规西药>益心舒胶囊+常规西药>麝香保心丸+常规西药>心可舒片+常规西药>常规西药;(4)在降低低密度脂蛋白胆固醇方面,排序依次为养心氏片+常规西药>益心舒胶囊+常规西药>冠心舒通胶囊+常规西药>丹蒌片+常规西药>心可舒片+常规西药>麝香保心丸+常规西药>常规西药;(5)在安全性方面,中成药联合常规西药的不良反应整体少于对照组。结论:本研究表明,中成药联合常规西药治疗稳定型心绞痛可显著提高其心绞痛及心电图疗效,同时具有调脂作用且安全性更好。但部分纳入研究的方法学质量不佳,故此结论需进一步在更多高质量研究中予以验证。展开更多
目的:应用网状Meta分析方法,比较不同活血化瘀类中成药治疗糖尿病视网膜病变(DR)的临床有效率、实验室指标改善情况及治疗的安全性。方法:通过检索中国知网(CNKI)、万方数据知识服务平台、维普期刊资源整合服务平台(VIP)、Web of Scienc...目的:应用网状Meta分析方法,比较不同活血化瘀类中成药治疗糖尿病视网膜病变(DR)的临床有效率、实验室指标改善情况及治疗的安全性。方法:通过检索中国知网(CNKI)、万方数据知识服务平台、维普期刊资源整合服务平台(VIP)、Web of Science及Pubmed等数据库获得关于活血化瘀类中成药治疗DR的临床随机对照研究,检索时限为建库至2023年4月10日,并对所检索到的文献进行筛选提取资料,通过Stata 16.0软件实施网状Meta分析。结果:最终纳入63项研究,分析结果显示:复方丹参滴丸+羟苯磺酸钙胶囊总体疗效最为显著;芪明颗粒+羟苯磺酸钙胶囊在改善DR患者视力方面疗效最为显著;复方血栓通胶囊+羟苯磺酸钙胶囊在改善DR患者黄斑厚度及视野灰度值方面疗效最好;和血明目片+羟苯磺酸钙胶囊在减小患者血管瘤体积方面疗效较好;治疗组与对照组均有不良反应报道,治疗组不良反应总体较少。结论:与单用羟苯磺酸钙胶囊比较,活血化瘀类中成药联合羟苯磺酸钙胶囊治疗DR患者,可提高临床有效率,改善患者实验室检查指标,减少不良反应。展开更多
目的:通过网状Meta分析的方法,评价不同中成药联合奥司他韦治疗流行性感冒的疗效及安全性,为临床选药用药提供循证医学证据。方法:检索PubMed、Embase、Cochrane Library、Web of Science、中国知网(CNKI)、维普(VIP)、万方(Wangfang)...目的:通过网状Meta分析的方法,评价不同中成药联合奥司他韦治疗流行性感冒的疗效及安全性,为临床选药用药提供循证医学证据。方法:检索PubMed、Embase、Cochrane Library、Web of Science、中国知网(CNKI)、维普(VIP)、万方(Wangfang)数据库,获取不同中成药治疗流行性感冒的随机对照试验(RCT),检索时间截至2023年11月1日,使用Revman5.3软件和Stata17软件进行统计学分析。结果:最终筛选出40篇RCTs,包含患者4738例,涉及8种治疗措施。研究结果表明,不同中成药联合奥司他韦在疗效方面均优于单纯使用奥司他韦。疏风解毒胶囊在总有效率和改善咳嗽方面效果最佳;小儿豉翘清热颗粒对于发热、咽痛症状效果明显;小儿柴桂退热颗粒缓解鼻塞流涕具有较大优势;在安全性方面,小儿豉翘清热颗粒不良反应率最低。结论:联合不同中成药可以提高奥司他韦对于流行性感冒的疗效。对小儿流感患者,可以优先选用小儿豉翘清热颗粒;针对成人流感患者,可以考虑使用疏风解毒胶囊或连花清瘟胶囊/颗粒。展开更多
目的:评估5种中成药与常规西药联合治疗成人变应性鼻炎的临床疗效。窗体顶端方法:采用计算机对中国知网、中国生物医学文献服务系统、万方数据库、维普数据库、PubMed、Embase、Web of Science和the Cochrane Library等8个数据库进行检...目的:评估5种中成药与常规西药联合治疗成人变应性鼻炎的临床疗效。窗体顶端方法:采用计算机对中国知网、中国生物医学文献服务系统、万方数据库、维普数据库、PubMed、Embase、Web of Science和the Cochrane Library等8个数据库进行检索,检索时间为建库至2024年2月21日,纳入鼻渊通窍颗粒、玉屏风颗粒、通窍鼻炎颗粒(胶囊)、鼻炎康片、香菊胶囊治疗成人变应性鼻炎的中文或英文随机对照试验(RCT)。运用Stata 16软件实施网状Meta分析,并使用Risk of bias 2工具辅助获得风险偏倚图。结果:最终纳入106篇RCT文献,样本量为11966例,其中观察组(在常规西药的基础上联合应用上述5种特定中成药之一)5996例,对照组(常规西药治疗)5970例。网状Meta分析结果表明,在提高临床总有效率方面,鼻炎康片+常规西药治疗表现出最佳的临床效果;在降低血清免疫学指标(免疫球蛋白E)方面,玉屏风颗粒+常规西药的临床效果最佳。结论:当前证据表明,在常规西药的基础上联合不同中成药治疗成人变应性鼻炎的疗效更好,但考虑纳入文献质量参差不齐,为了进一步验证该结论,未来需要开展更多大规模、高质量、多元化的RCT。展开更多
目的了解中药配方颗粒相关研究开展现状。方法检索1993年至2022年中药配方颗粒相关专利文献与学术论文。其中专利文献通过检索incoPat全球专利数据库获得;学术论文中,中文文献来自中国知网数据库,英文文献来自Web of Science核心合集数...目的了解中药配方颗粒相关研究开展现状。方法检索1993年至2022年中药配方颗粒相关专利文献与学术论文。其中专利文献通过检索incoPat全球专利数据库获得;学术论文中,中文文献来自中国知网数据库,英文文献来自Web of Science核心合集数据集;对中药配方颗粒历年专利申请及公开数量、专利权人排名、专利技术功效分布、历年论文发表量、热点关键词、发文机构进行汇总及可视化分析。结果当前中药配方颗粒领域论文发文量与专利申请及公开数量均处于其发展历程中的高位;药品生产企业是专利的主要持有者;专利技术功效专注于便利性提高、复杂性降低、效率提高等;学术论文的主要发表者是中医药院校,中文文献研究热点集中于中药配方颗粒的质量控制、临床应用等,英文文献则集中于药物化学成分、随机对照试验等。结论中药配方颗粒的研究热度处在历史较高水平,且热度预计将仍会持续。展开更多
文摘Objective To explore the rules and characteristics of the adverse drug reactions(ADRs)of three Chinese patent medicines and three herbal formulas for the treatment of COVID-19,and to provide a reference for clinical safe medication.Methods The cases and ADR reports of the three Chinese patent medicines and three herbal formulas in PubMed,Web of Science,Springer Link,CNKI,Wanfang and VIP database were retrieved from December 2019 to May 2021.Then we extracted and analyzed the effective information included in the literature.Results and Conclusion According to the pre-developed retrieval plan,a total of 136 documents were obtained,and a total of 6 documents met the inclusion criteria finally.553 patients used three Chinese patent medicines and three herbal formulas,and there were 133 cases of adverse reactions.The adverse reactions of patients taking the three Chinese patent medicines and three herbal formulas can all be explained under the theory of traditional Chinese medicine,and the adverse reactions can be eliminated by adding or subtracting the flavor of the medicine or stopping the medicine.
基金supported by National Natural Science Foundation of China:International (regional)cooperation and exchange project (81820108033)China Academy of Chinese Medical Sciences Youth Talent Project (ZZ14-YQ-020)。
文摘Objective:To systematically review the efficacy and clinical safety of Qizhi Weitong Granules(气滞胃痛颗粒)(QZWT)in the treatment of irritable bowel syndrome with predominant constipation(IBS-C).Methods:Randomized controlled trials(RCTs)of QZWT in patients with IBS-C were retrieved from Pub Med,EMBASE,Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang,Chinese Scientific Journals Database(VIP),and Chinese Biological Medical Database(CBM)from inception to December 3,2022.Conventional meta-analysis with random-effects model or fixed-effects model and trial sequential analysis(TSA)were performed by Review Manager 5.4,Stata and TSA software.Results:A total of 4 RCTs and 368 patients with IBS-C were included in this study.The findings of the meta-analysis indicated that the cure and efficacy rate of the experimental group was significantly higher than that of the control group[RR=2.19;(95%CI,1.35–3.55),P<0.01;RR=1.14;(95%CI,1.03–1.27),P<0.05],while the result of Bristol Score was negative.The funnel plot was probably symmetry,and the P value was>0.05 in the Egger test,which confirmed the nonexistence of significant publication bias in this outcome.TSA showed the cumulative z-value crossed the traditional threshold and TSA threshold,while it didn't get to the required information size.Finally,2 studies reported adverse events after QZWT treatment,including 3 cases of diarrhea.No serious adverse events were reported.Conclusion:QZWT was an effective and safe complementary therapy in the treatment of IBS-C with no obvious adverse reactions.TSA analysis confirmed our meta-analysis results.Therefore,QZWT may be a potential candidate for the treatment of IBS-C.However,due to the limited quality of current studies,more long-term,randomized,double-blinded clinical trials are needed in future studies.
基金Applied technology research and development plan of Heilongjiang province(No.GY2019YF0237)National training program for innovative young talents if traditional Chinese medicine(No.14061190007)。
文摘Objective:To evaluate the efficacy and safety of Yiqi Huoxue oral Chinese patent medicine in the treatment of angina pectoris.Methods:the databases of EMBASE,PubMed,CNKI,Wanfang and VIP were searched by computer,and the randomized controlled trial(RCT)of Yiqi Huoxue Chinese patent medicine in the treatment of angina pectoris of coronary heart disease(CHD)was searched until December 2019.By using stata15.1 software,the total clinical effective rate,the improvement rate of ECG,the improvement rate of angina pectoris,the attack frequency and duration of angina pectoris were taken as the outcome indicators for network meta analysis and mapping.Results:51 RCTs were included,including 9 kinds of traditional Chinese medicine.The results of network meta analysis showed that:in terms of clinical total effective rate,the order was Shexiang Baoxin Pill(78.2%)>xueshuanxinming tablet>Dengzhan Shengmai capsule>Shengui Capsule>Tongxinluo capsule>Tongmai Yangxin pill>Yangxin tablet>Shexiang Tongxin drop pill>Naoxintong capsule;the improvement of ECG was Tongmai Yangxin pill(85.2%)>Yangxin tablet>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Shexiang Baoxin Pill>Tongxinluo gum Capsule>Shengui Capsule>Naoxintong capsule;in order to reduce the frequency and duration of angina pectoris,they are conventional Naoxintong capsule(88.6%)>Shengui Capsule>Tongmai Yangxin pill>Shexiang Baoxin Pill>xueshuanxinmingpian>Tongxinluo capsule>Shexiang Tongxin drop pill>Dengzhan Shengmai capsule;Shexiang Baoxin Pill(66.9%)>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Tongxinluo capsule>xueshuanxinmingning capsule Tablet>Tongmai Yangxin pill.Conclusion:Traditional Chinese medicine combined with western medicine has obvious advantages in the treatment of angina pectoris.Shexiang Baoxin Pill,Dengzhan Shengmai capsule and Tongmai Yangxin pill can be given priority.
基金Supported by the National Natural Science Foundation of China(No20605020)Foundation of National Excellent Ph D Thesis and Distinguished Young Scholars of Jilin Province, China(No20060112)
文摘A capillary electrophoresis with electrochemical detection(CE-ED) method was developed for the quality analysis of herbal medicine products prepared from the same herb of Herba Sarcandrae: Fufang Caoshanhu tablets, Qingrexiaoyanning capsules, and Xuekang oral liquids. Under the optimal analysis conditions, the low detection limit[l.0×10^-7 mol/L(S/N=3)] and the wide linear range(1.0×10^-7-1.0×10^-4 mol/L) were obtained for quality standard compound of isofraxidin. The precisions of the peak current and the migration time(as RSDs) for the real sample analysis were 2.0%-2.6%, and 1.2%-1.8% for isofraxidin, respectively. The contents of isofraxidin detected were 15.77 μg/tablet, 0.48 mg/capsule, 1.2 mg/ampoule(Jiangxi), and 0.44 mg/ampoule(Dalian) for Fufang Caoshanhu tablets, Qingrexiaoyanning capsules, and Xuekang oral liquids from different manufacturers, respectively. Quality estimate was conducted by comparing the contents of isofraxidin in the herbal medicine products with the demanded values of Chinese pharmacopeia. In addition, based on their own unique CE-ED profiles(namely, CE-ED electropherograms) the Xuekang oral liquids from the different manufacturers could be easily identified.
文摘目的:应用网状Meta分析方法,比较不同活血化瘀类中成药治疗糖尿病视网膜病变(DR)的临床有效率、实验室指标改善情况及治疗的安全性。方法:通过检索中国知网(CNKI)、万方数据知识服务平台、维普期刊资源整合服务平台(VIP)、Web of Science及Pubmed等数据库获得关于活血化瘀类中成药治疗DR的临床随机对照研究,检索时限为建库至2023年4月10日,并对所检索到的文献进行筛选提取资料,通过Stata 16.0软件实施网状Meta分析。结果:最终纳入63项研究,分析结果显示:复方丹参滴丸+羟苯磺酸钙胶囊总体疗效最为显著;芪明颗粒+羟苯磺酸钙胶囊在改善DR患者视力方面疗效最为显著;复方血栓通胶囊+羟苯磺酸钙胶囊在改善DR患者黄斑厚度及视野灰度值方面疗效最好;和血明目片+羟苯磺酸钙胶囊在减小患者血管瘤体积方面疗效较好;治疗组与对照组均有不良反应报道,治疗组不良反应总体较少。结论:与单用羟苯磺酸钙胶囊比较,活血化瘀类中成药联合羟苯磺酸钙胶囊治疗DR患者,可提高临床有效率,改善患者实验室检查指标,减少不良反应。
文摘目的:通过网状Meta分析的方法,评价不同中成药联合奥司他韦治疗流行性感冒的疗效及安全性,为临床选药用药提供循证医学证据。方法:检索PubMed、Embase、Cochrane Library、Web of Science、中国知网(CNKI)、维普(VIP)、万方(Wangfang)数据库,获取不同中成药治疗流行性感冒的随机对照试验(RCT),检索时间截至2023年11月1日,使用Revman5.3软件和Stata17软件进行统计学分析。结果:最终筛选出40篇RCTs,包含患者4738例,涉及8种治疗措施。研究结果表明,不同中成药联合奥司他韦在疗效方面均优于单纯使用奥司他韦。疏风解毒胶囊在总有效率和改善咳嗽方面效果最佳;小儿豉翘清热颗粒对于发热、咽痛症状效果明显;小儿柴桂退热颗粒缓解鼻塞流涕具有较大优势;在安全性方面,小儿豉翘清热颗粒不良反应率最低。结论:联合不同中成药可以提高奥司他韦对于流行性感冒的疗效。对小儿流感患者,可以优先选用小儿豉翘清热颗粒;针对成人流感患者,可以考虑使用疏风解毒胶囊或连花清瘟胶囊/颗粒。
文摘目的:评估5种中成药与常规西药联合治疗成人变应性鼻炎的临床疗效。窗体顶端方法:采用计算机对中国知网、中国生物医学文献服务系统、万方数据库、维普数据库、PubMed、Embase、Web of Science和the Cochrane Library等8个数据库进行检索,检索时间为建库至2024年2月21日,纳入鼻渊通窍颗粒、玉屏风颗粒、通窍鼻炎颗粒(胶囊)、鼻炎康片、香菊胶囊治疗成人变应性鼻炎的中文或英文随机对照试验(RCT)。运用Stata 16软件实施网状Meta分析,并使用Risk of bias 2工具辅助获得风险偏倚图。结果:最终纳入106篇RCT文献,样本量为11966例,其中观察组(在常规西药的基础上联合应用上述5种特定中成药之一)5996例,对照组(常规西药治疗)5970例。网状Meta分析结果表明,在提高临床总有效率方面,鼻炎康片+常规西药治疗表现出最佳的临床效果;在降低血清免疫学指标(免疫球蛋白E)方面,玉屏风颗粒+常规西药的临床效果最佳。结论:当前证据表明,在常规西药的基础上联合不同中成药治疗成人变应性鼻炎的疗效更好,但考虑纳入文献质量参差不齐,为了进一步验证该结论,未来需要开展更多大规模、高质量、多元化的RCT。
文摘目的了解中药配方颗粒相关研究开展现状。方法检索1993年至2022年中药配方颗粒相关专利文献与学术论文。其中专利文献通过检索incoPat全球专利数据库获得;学术论文中,中文文献来自中国知网数据库,英文文献来自Web of Science核心合集数据集;对中药配方颗粒历年专利申请及公开数量、专利权人排名、专利技术功效分布、历年论文发表量、热点关键词、发文机构进行汇总及可视化分析。结果当前中药配方颗粒领域论文发文量与专利申请及公开数量均处于其发展历程中的高位;药品生产企业是专利的主要持有者;专利技术功效专注于便利性提高、复杂性降低、效率提高等;学术论文的主要发表者是中医药院校,中文文献研究热点集中于中药配方颗粒的质量控制、临床应用等,英文文献则集中于药物化学成分、随机对照试验等。结论中药配方颗粒的研究热度处在历史较高水平,且热度预计将仍会持续。